A surgeon at the University of Pittsburgh Medical Center (UPMC) has implanted the first patient in the US with a new wireless retinal device. Read more
Aussie corneal engineering research earns major backing
A Melbourne researcher has received a major funding boost to progress development of a tissue-engineered corneal endothelium for transplant, which could help overcome a global shortage of corneal donations in future. Read more
Gene responsible for ageing of eye found
In a discovery that could have significant implications for how age-related ocular diseases are diagnosed and treated, researchers have pinpointed a specific gene linked to the effect ageing has on the eye. Read more
Study highlights biomarker for discontinuing anti-VEGF treatment
A new study has demonstrated that a particular biomarker can be used to select which age-related macular degeneration (AMD) patients can discontinue their anti-VEGF therapy. Read more
Novartis secures approval for AMD drug in Australia
Australia’s ophthalmic community has welcomed the approval of Novartis’ latest therapy for neovascular age-related macular degeneration (nAMD). Advocates hope the decision will lift treatment adherence rates across the country. Read more
Opthea hits recruitment target for diabetic study
Melbourne biopharmaceutical company Opthea has completed the patient recruitment phase for the latest trial of its novel therapy for diabetic macular edema (DME). Read more
Major Melbourne study a world-first for AMD
An Australian-led study has received $5 million to undertake the world’s most intensive investigation into why a particular group of age-related macular degeneration (AMD) patients are at greater risk of vision loss. Read more
Novartis targets Europe for next-generation AMD treatment
Novartis’ new therapy for neovascular age-related macular degeneration (nAMD) has advanced part-way through the European regulatory process after winning the approval of independent advisors. Read more
Warmth may improve effectiveness of anti-VEGF injections
Inconsistent or ineffective age-related macular degeneration (AMD) treatments might be solved by an easy solution, according to new research from the California Institute of Technology. Read more
Australian biotech raises an additional $50 million for AMD drug
Melbourne-based biotech company Opthea has announced it has secured commitments from both Australian and international investors for an additional $50 million to put towards the development of its treatment for neovascular age-related macular degeneration (AMD). Read more